Lower Lugol's Solution Concentration on Reducing the Adverse Symptoms of Chromoendoscopy With Iodine Staining
- Conditions
- Image QualityMucosal Irritation
- Interventions
- Drug: 1.2% Lugol's solutionDrug: 1.0% Lugol's solutionDrug: 0.8% Lugol's solutionDrug: 0.6% Lugol's solutionDrug: 0.4% Lugol's solution
- Registration Number
- NCT03180944
- Lead Sponsor
- Shandong University
- Brief Summary
This study was to test an optimal concentration of Lugol's solution which can reduce the mucosal irritation and provide high image quality to ensure endoscopy examination by a randomized blinded controlled trial.
- Detailed Description
It is widely accepted that chromoendoscopy using Lugol's solution is effective for the detection of early esophageal squamous neoplasia. However, this modality may cause severe chest pain and discomfort owing to mucosal irritation. The conventional concentration of Lugol's solution is in the range of 1.2% to 2.5% . Image quality can be guaranteed with this range of Lugol's solution. However, lead to retrosternal pain and discomfort, and can even induce erosion or ulceration in the esophagus and stomach. This study was to test whether a lower concentration of Lugol's solution, which has minimal mucosal irritation, can provide satisfied image quality by a randomized blinded controlled trial.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
- patients in the high-risk population of ESCC;
- or general risk population of ESCC between 40 to 74 years old. Definition of high-risk population of ESCC is list in supporting information33.
Exclusion criteria included the following:
- with obvious abnormalities in stomach, confirmed by either white-light endoscopy (WLE) or pCLE, including gastric cancer, acute erosive and hemorrhagic gastritis, chronic atrophic gastritis, H. pylori infection and severe bile reflux gastritis;
- advanced esophageal carcinoma;
- known esophageal surgery or endoscopic treatment;
- known esophageal radiotherapy or chemotherapy;
- esophageal stenosis;
- food retention;
- allergy to iodine or fluorescein sodium;
- hyperthyroid;
- coagulopathy;
- acute bleeding;
- severe organ failure;
- pregnant or breastfeeding women.
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1.2% Lugol's solution 1.2% Lugol's solution This group patients were given concentrations of 1.2% Lugol's solution for chromoendoscopy. 1.0% Lugol's solution 1.0% Lugol's solution This group patients were given concentrations of 1.0% Lugol's solution for chromoendoscopy. 0.8% Lugol's solution 0.8% Lugol's solution This group patients were given concentrations of 0.8% Lugol's solution for chromoendoscopy. 0.6% Lugol's solution 0.6% Lugol's solution This group patients were given concentrations of 0.6% Lugol's solution for chromoendoscopy. 0.4% Lugol's solution 0.4% Lugol's solution This group patients were given concentrations of 0.4% Lugol's solution for chromoendoscopy.
- Primary Outcome Measures
Name Time Method Image Quality intraoperative Image quality is blindly quantified by a 4-point scale from the endoscopists. A higher score representing higher image quality.
- Secondary Outcome Measures
Name Time Method Adverse Events 24 hours Both a written and oral form of the Numerical Rating Scale (NRS) was provided to the patients after the endoscopy examination, used for measuring patients' retrosternal pain, retrosternal discomfort, nausea, abdominal discomfort and others. In NRS, 0 is painless, 10 is the most severe pain, less than 4 is mild pain (pain does not affect sleep), 4-6 is moderate pain, and more than 7 is severe pain (pain means unable to sleep or wake up from sleep).
Severe Adverse Events 24 hours Severe adverse events includes allergic reactions, esophageal burns, spasms and even perforation.
Histology analysis 3-5days All specimens were evaluated by two experienced pathologists blind to the groups of the patients. The macroscopic and histologic diagnosis were made based on Paris classification and Vienna classification, respectively.
Gastric Mucosa Injury 1 months The gastric mucosal injury caused by Lugol's solution is defined as post-staining gastritis score minus pre-staining gastritis score in pCLE. The confocal gastritis was graded 0 to 3,according to pit patterns, capillaries, and fluorescein leakage. A higher score representing more serious injury.
Tolerance intraoperative The 4-point scale was used to assess the tolerance of endoscopist to the esophageal spasm caused by Lugol's solution which prevent endoscopy from passing. 1-4 means the resistance as intolerable, tolerable, mild, or non-existing.
Trial Locations
- Locations (1)
Qilu Hospital, Shandong University
🇨🇳Jinan, Shandong, China